Gnasso A, Lehner B, Haberbosch W, Leiss O, von Bergmann K, Augustin J
Metabolism. 1986 May;35(5):387-93. doi: 10.1016/0026-0495(86)90125-3.
The lipid lowering agent Gemfibrozil was tested in 8 normolipidemic subjects during a three-month intake. Plasma triglycerides decreased by 41% and Very Low Density Lipoprotein (VLDL) triglycerides decreased by 54%. The reduction of plasma cholesterol, less marked (by 10%), was due to a decrease of Low Density Lipoprotein by 20% while High Density Lipoprotein (HDL) increased up to 30%. The separation of HDL demonstrated that only HDL3 were increased. The determination of the apoproteins in plasma and lipoprotein fractions showed similar results with a decrease of apo B (by 20%) and an increase of apo A-I and apo A-II, mainly in the HDL3 fraction. Plasma postheparin lipolytic activities (PHLA) were not influenced by the therapy and no correlation was found between these activities and any of the plasma or lipoprotein lipids. The apo C-III/apo C-II ratio in VLDL decreased by 30%; however, no correlation was found between this ratio in plasma as well as VLDL and triglycerides. In addition, the Intra Venous Fat Tolerance Test did not demonstrate any improvement of the clearance of exogenous fat. The lipid lowering efficacy of Gemfibrozil, its collateral effects, and the possible mechanisms of action are discussed.
在8名血脂正常的受试者中进行了为期三个月的降脂药物吉非贝齐试验。血浆甘油三酯下降了41%，极低密度脂蛋白（VLDL）甘油三酯下降了54%。血浆胆固醇的降低幅度较小（10%），这是由于低密度脂蛋白降低了20%，而高密度脂蛋白（HDL）升高了30%。HDL的分离显示只有HDL3升高。血浆和脂蛋白组分中载脂蛋白的测定结果相似，apo B降低了20%，apo A-I和apo A-II升高，主要在HDL3组分中。血浆肝素后脂解活性（PHLA）不受该治疗影响，且未发现这些活性与任何血浆或脂蛋白脂质之间存在相关性。VLDL中的apo C-III/apo C-II比值下降了30%；然而，血浆以及VLDL中的该比值与甘油三酯之间未发现相关性。此外，静脉脂肪耐量试验未显示外源性脂肪清除有任何改善。讨论了吉非贝齐的降脂疗效、其副作用以及可能的作用机制。
